Keymed Biosciences Inc.
2162.HK · HKSE
Financial statements
Annual and quarterly income, balance-sheet, cash-flow and key-statistics data.
Income statement
| Period | Revenue | Gross profit | Operating income | Net income | EPS |
|---|---|---|---|---|---|
| 2022 FY | 100.06M | 97.48M | -543.81M | -308.12M | -1.18 |
| 2023 FY | 354.10M | 317.22M | -434.80M | -359.36M | -1.37 |
| 2024 FY | 428.12M | 415.92M | -618.10M | -515.24M | -1.97 |
| 2025 FY | 697.77M | 516.51M | -584.85M | -509.11M | -1.86 |
Balance sheet
| Period | Total assets | Liabilities | Cash | Debt | Equity |
|---|---|---|---|---|---|
| 2022 FY | 3.93B | 593.10M | 604.07M | 121.97M | 3.34B |
| 2023 FY | 3.88B | 896.11M | 851.03M | 418.71M | 2.99B |
| 2024 FY | 3.77B | 1.29B | 418.41M | 753.24M | 2.47B |
| 2025 FY | 4.22B | 1.44B | 543.17M | 788.88M | 2.78B |
Cash flow
| Period | Operating cash flow | Capital expenditure | Free cash flow | Dividends paid | Net cash change |
|---|---|---|---|---|---|
| 2022 FY | -401.93M | -279.55M | -681.48M | — | -916.55M |
| 2023 FY | -303.62M | -382.61M | -686.23M | — | 246.96M |
| 2024 FY | -789.63M | -214.50M | -1.00B | — | -432.62M |
| 2025 FY | -712.41M | -336.48M | -1.05B | — | 84.93M |
Key statistics
| Period | Market cap | Enterprise value | P/E | Price / sales | Debt / equity |
|---|---|---|---|---|---|
| 2022 FY | 11.76B | 11.28B | — | — | — |
| 2023 FY | 11.63B | 11.20B | — | — | — |
| 2024 FY | 7.60B | 7.94B | — | — | — |
| 2025 FY | 13.15B | 13.40B | — | — | — |
Income statement
| Period | Revenue | Gross profit | Operating income | Net income | EPS |
|---|---|---|---|---|---|
| 2024 Q2 | 54.68M | 50.95M | -393.28M | -336.75M | -1.29 |
| 2024 Q4 | 373.44M | 364.98M | -224.82M | -178.50M | -0.68 |
| 2025 Q2 | 498.75M | 465.28M | -122.19M | -78.84M | -0.30 |
| 2025 Q4 | 213.93M | 111.95M | -471.09M | -436.39M | -1.46 |
Balance sheet
| Period | Total assets | Liabilities | Cash | Debt | Equity |
|---|---|---|---|---|---|
| 2024 Q2 | 3.81B | 1.17B | 709.91M | 751.34M | 2.64B |
| 2024 Q4 | 3.77B | 1.29B | 418.41M | 753.24M | 2.47B |
| 2025 Q2 | 4.63B | 1.44B | 941.71M | 872.30M | 3.19B |
| 2025 Q4 | 4.22B | 1.44B | 543.17M | 788.88M | 2.78B |
Cash flow
| Period | Operating cash flow | Capital expenditure | Free cash flow | Dividends paid | Net cash change |
|---|---|---|---|---|---|
| 2024 Q2 | -365.92M | -107.43M | -473.35M | — | 709.91M |
| 2024 Q4 | -423.71M | -100.49M | -524.20M | — | -709.91M |
| 2025 Q2 | -180.96M | -149.57M | -330.53M | — | 941.71M |
| 2025 Q4 | -368.93M | -184.05M | -552.97M | — | -383.48M |
Key statistics
| Period | Market cap | Enterprise value | P/E | Price / sales | Debt / equity |
|---|---|---|---|---|---|
| 2024 Q2 | 7.82B | 7.86B | — | — | — |
| 2024 Q4 | 7.61B | 7.95B | — | — | — |
| 2025 Q2 | 11.08B | 11.01B | — | — | — |
| 2025 Q4 | 14.34B | 14.59B | — | — | — |